STTR PHASE I: Nano-Needle DNA Biosensor For Iin-Situ Direct Detection

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 0740525
Agency Tracking Number: 0740525
Amount: $64,996.00
Phase: Phase I
Program: STTR
Awards Year: 2008
Solicitation Year: N/A
Solicitation Topic Code: EL
Solicitation Number: NSF 07-551
Small Business Information
NanoFacture, Inc.
3983 Research Park Dr. Suite 100, Ann Arbor, MI, 48108
DUNS: 620837299
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Kyonghoon Lee
 (734) 255-4311
Business Contact
 Kyonghoon Lee
Title: PhD
Phone: (734) 255-4311
Research Institution
 University of Washington
 Kyonghoon Lee
 1100 NE 45th Street
Suite 300
Seattle, WA, 98105
 (206) 543-4043
 Nonprofit college or university
This STTR Phase I research proposal will demonstrate the feasibility of a nanoscale needle (nano-needle) probe biosensor assaying low-abundance nucleic acids without target-/signal amplification. The unique point in the proposed work lies in the combined use of dielectrophoresis and capillary action to fabricate a high-aspect ratio nano-needle made of a hybrid nanomaterial and to operate the nano-needle as a biosensor, achieving high sensitivity through size-exclusive sample concentration. The company has already succeeded in nonspecifically sampling/assaying intercalator-treated lambda-DNA spiked into a buffer or cell solution in a quantitative manner. The sensitivity of this achievement was around 10pg/mL (0.3fM) which is comparable to the concentration of naturally occurring DNA species and sufficient for screening/detection of circulating DNA in blood (sub-50ng/mL). The method will pave the way to high throughput fabrication of high aspect ratio nano-needle structures and the application to the biosensing platform. The proposed nano-needle biosensor device will enable simple, rapid, yet sensitive detection without target-/signal amplification and minimize the operation in terms of the physical size, corresponding energy consumption, sample size, and sample preparation time as a field-deployable device. The biosensor is aimed for point-of-care-testing using minimally treated or raw samples. Eventually, the device will be applicable to nucleic acid testing (NAT) for rapid screening of diseases (e.g. cancer), which is enabled through minimally treated samples.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government